The global antibiotics market is valued at USD 55.60 billion in 2025 and is projected to reach USD 70.64 billion by 2031, growing at a 4.07% CAGR. Broad-spectrum antibiotics dominate with 65.53% market share, while Asia-Pacific is expected to register the fastest growth. Market expansion is driven by rising bacterial infections, antimicrobial resistance concerns, and innovation in next-generation therapies.

Exelixis, a U.S.-based biotech company specializing in cancer treatments, is positioned for market-beating returns through its growing pipeline beyond its blockbuster cabozantinib drug. The company reported 57.9% EPS growth in 2025 and recently received FDA approval for zanzalintinib for metastatic colorectal cancer. With zanzalintinib in four phase 3 trials and strategic partnerships with major pharma companies, Exelixis aims to become a top-five solid tumor oncology company.

Fight Colorectal Cancer launches its fifth annual United in Blue installation on the National Mall from March 1-14, 2026, featuring over 27,000 blue flags representing people under 50 projected to be diagnosed with colorectal cancer in 2030. The installation comes as new American Cancer Society research confirms colorectal cancer has become the deadliest cancer for Americans under 50, with mortality increasing in 2025.

Despite a 35% stock decline over the past six months due to competition concerns, Veeva Systems remains a solid long-term buy. The company's specialized cloud services for life sciences companies create strong switching costs and competitive advantages. With a goal to double revenue to $6 billion by 2030 and a history of meeting targets, Veeva is well-positioned to capitalize on the expanding life sciences industry.

Merck & Co. announced a restructuring of its Human Health business, creating separate Oncology and Specialty, Pharma & Infectious Diseases units to enhance commercial execution. The move comes as the company prepares for patent loss of its blockbuster Keytruda in 2028 and plans to launch over 20 new growth drivers. MRK shares rose 1.42% in premarket trading, outperforming a broader market decline.

Merck announced positive Phase 3 SMART trial data for Enflonsia (clesrovimab), its RSV monoclonal antibody treatment, showing consistent safety in children under 2 years old. The company is seeking FDA approval to expand the indication to children at increased risk for severe RSV disease for a second RSV season. The data will be submitted to the FDA for evaluation.

Merck & Co. announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence and advanced analytics in drug discovery. The partnership will utilize Mayo Clinic's multimodal data to validate AI models and improve drug development, initially focusing on inflammatory bowel disease, atopic dermatitis, and multiple sclerosis. Despite the positive announcement, Merck shares underperformed the healthcare sector on the trading day.

The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.

With 74% of institutional money managers expecting a market correction in 2026, the article recommends two defensive healthcare stocks—AbbVie and Merck—that historically perform well during downturns. Both companies offer robust dividends with yields around 2.7-3.1%, have raised dividends for 13+ consecutive years, and are projected to deliver strong growth in 2026.

Eli Lilly acquired Boston-based biotech Orna Therapeutics for $2.4 billion to develop circular RNA-based gene therapies for autoimmune diseases. The deal represents Lilly's continued effort to fill its drug pipeline beyond its blockbuster GLP-1 drug tirzepatide. Orna's lead candidate ORN-252 uses innovative in vivo chimeric antigen receptor T-cell technology and is clinical trial-ready, though several years away from commercial sales.

With the Dow Jones Industrial Average surging past 50,000, two blue-chip stocks stand out as undervalued opportunities. Verizon Communications trades at a forward P/E of 9.1 with 19% upside potential and a 6% dividend yield, while Merck & Company trades at 16x trailing earnings with an 18.7% undervaluation and a robust drug pipeline offsetting patent cliff concerns.

The FDA approved Merck's Keytruda and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for previously treated ovarian cancer patients. The Phase 3 KEYNOTE-B96 trial showed the treatment reduced disease progression or death risk by 28% and death risk by 24% compared to placebo. Keytruda generated $8.37 billion in global sales in Q4 2025, up 7% year-over-year.